Cathal Grant
Psychiatry · Bedford, TXNPI 1255384145
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $320,754 of the $414,461 with a category attached, or 77.4%. 38 manufacturers reported payments, led by AbbVie at 37.2% of the total. Reporting peaked in 2023 at $87,770 and has fallen 57.2% since, to $37,539 in 2025. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,856 payments — averaging $223.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$154K
- Supernus Pharmaceuticals, Inc.$74K
- Tris Pharma Inc$53K
- Axsome Therapeutics, Inc.$32K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$31K
- Vanda Pharmaceuticals Inc.$25K
- plus $46K from 32 others
What the payments were for
- Consulting fees$20,3155%
- Speaking & faculty fees$320,75477%
- Travel & lodging$35,3049%
- Food & beverage$37,8949%
- Education$1940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$148,405
- QELBREE$67,965
- LYBALVI$53,126
- Quillivant$50,665
- Dyanavel XR$50,634
- Quillichew ER$50,426
- Auvelity$30,555
- CAPLYTA$28,417
- Fanapt$23,279
- REXULTI$3,689
- Equetro$3,632
- COBENFY$2,325
- Austedo XR$1,121
- Dayvigo$1,000
- LATUDA$995
- UZEDY$840
- Adzenys XR-ODT$675
- Cotempla XR-ODT$675
- Azstarys$477
- ABILIFY MYCITE$175
How this compares
$414,461 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 33 | $16,353 |
| RexultiBrexpiprazole | 12 | $16,346 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 218 | $7,678 |
| Lisdexamfetamine Dimesylate | 35 | $7,439 |
| AzstarysSerdexmethylphen/Dexmethylphen | 13 | $5,025 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 53 | $3,895 |
| Methylphenidate Hcl | 46 | $2,161 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 24 | $1,718 |
| Dextroamphetamine Sulfate | 14 | $1,179 |
| Clozapine | 23 | $1,084 |
| Bupropion XlBupropion Hcl | 39 | $980 |
| Clonazepam | 99 | $978 |
| Zolpidem Tartrate | 49 | $952 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 13 | $817 |
| Alprazolam | 126 | $659 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $1,259 | $16,35333 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $5,199 | $16,34612 claims |
| Corium, LLCAzstarys | $1,506 | $5,02513 claims |
| Almatica Pharma LLCSertraline Hcl | $64 | $30117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Bedford
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
- Alice MaoHouston$850K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.